Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR - ICR / Cancer Research Society Partnership - Research Grants

University of Ottawa

$60,000.00

Pre-clinical development of an extended-release nanosphere formulation to deliver a novel colorectal cancer stem cell-targeting agent

FY 2021-22

Summary
Cancer stem cells (CSC) are a rare population of malignant cells responsible for tumor initiation, relapse, and resistance to current treatments. With the precious support of the Cancer Research Society, we recently discovered the important role of a protein called G9a, which controls the structure and function of chromosomes (epigenetics) in human colorectal CSCs. Our laboratory is working to develop new medicines to block the activity of G9a in colorectal CSCs without damaging healthy tissues, with the ultimate goal of eradicating colon cancer. We found a marketed drug with the capacity to block the activity of G9a and to suppress colorectal CSCs in mice. Notably, we also observed that colorectal cancer cells do not become resistant to our candidate molecule after being exposed to it, which is very unusual compared to other chemotherapy drugs currently used to treat patients. This unique aspect represents an opportunity to develop new delivery methods to keep colorectal cancer in check with long-acting formulations of our drug. This would improve patients' life quality with less frequent visits to the clinic. Thus, with renewed support from the Cancer Research Society, we will test the efficacy of a formulation of our drug encapsulated in microscopic biodegradable spheres to eliminate colorectal CSCs in mice. This specific drug delivery method will allow the treatment to persist over several weeks and should block the the tumor progression toward metastasis in other organs.
Program
CIHR - ICR / Cancer Research Society Partnership - Research Grants
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
468009
Name
Benoit Yannick D
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cancer Research Society Inc.; Cancer Research Society Inc.
Instname2
Cancer Research
Prcname2
Special Cases
Projecttitle
Pre-clinical development of an extended-release nanosphere formulation to deliver a novel colorectal cancer stem cell-targeting agent
Programtype2
Operating Grants
Orgnameinp2
University of Ottawa
Cihramount2
$60,000
Cihrequipment2
$0
Programname2
CIHR - ICR / Cancer Research Society Partnership - Research Grants
Keyworddelim
Chemotherapy And Radiotherapy ; Colorectal Cancer; Drug Repurposing ; Translational Research
Abstract
Cancer stem cells (CSC) are a rare population of malignant cells responsible for tumor initiation, relapse, and resistance to current treatments. With the precious support of the Cancer Research Society, we recently discovered the important role of a protein called G9a, which controls the structure and function of chromosomes (epigenetics) in human colorectal CSCs. Our laboratory is working to develop new medicines to block the activity of G9a in colorectal CSCs without damaging healthy tissues, with the ultimate goal of eradicating colon cancer. We found a marketed drug with the capacity to block the activity of G9a and to suppress colorectal CSCs in mice. Notably, we also observed that colorectal cancer cells do not become resistant to our candidate molecule after being exposed to it, which is very unusual compared to other chemotherapy drugs currently used to treat patients. This unique aspect represents an opportunity to develop new delivery methods to keep colorectal cancer in check with long-acting formulations of our drug. This would improve patients' life quality with less frequent visits to the clinic. Thus, with renewed support from the Cancer Research Society, we will test the efficacy of a formulation of our drug encapsulated in microscopic biodegradable spheres to eliminate colorectal CSCs in mice. This specific drug delivery method will allow the treatment to persist over several weeks and should block the the tumor progression toward metastasis in other organs.
Competitiondate
202202
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Benoit, Yannick D
Approvedterm
2 ans 0 mois
Cihrcontribution2
Inst of Cancer Research~ $60,000~ $0~
University of Ottawa - $60,000 Grant (2021-22) | Canada Spends